Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3962248 | 0.89 | KIF11 (0.46) | KIF11CYP11B1CYP11B2SLC22A12NISCH | |
| SCHEMBL3056563 | 0.81 | NOS3 (0.45) | KIF11NISCHALDH1A1LMNA | |
| SCHEMBL3066116 | 0.77 | MAPK10 (0.48) | NISCHHDAC1ALDH1A1LMNA | |
| SCHEMBL3960629 | 0.76 | KIF11 (0.38) | KIF11CYP11B1CYP11B2NISCH | |
| SCHEMBL28244146 | 0.75 | KIF11 (0.49) | KIF11ALDH1A1LMNA | |
| SCHEMBL3073686 | 0.74 | MAPK10 (0.51) | CYP11B1CYP11B2NISCHALDH1A1LMNA | |
| SCHEMBL31344191 | 0.71 | NOS2 (0.46) | KIF11CYP11B1CYP11B2NISCH | |
| SCHEMBL28307250 | 0.70 | SIGMAR1 (0.41) | — | |
| SCHEMBL31344192 | 0.70 | CHRM1 (0.40) | KIF11CYP11B1CYP11B2NISCHNPC1 | |
| SCHEMBL3070384 | 0.69 | NISCH (0.38) | KIF11CYP11B1CYP11B2NISCHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009038812-A1 | CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038812-A1 | CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | KIF11 2948/4885CYP11B1 3209/4885CYP11B2 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.